158985-37-6

Basic information

• Product Name: TERT-BUTYL 4-[4-(HYDROXYMETHYL)PHENYL]TETRAHYDRO-1(2H)-PYRAZINECARBOXYLATE
• Synonyms: BUTTPARK 98\06-99;[4-(4-TERT-BUTOXYCARBONYL)PIPERAZINE]BENZYL ALCOHOL;1-(4-HYDROXYMETHYL-PHENYL)-PIPERAZINE-4-CARBOXYLIC ACID TERT-BUTYL ESTER;TERT-BUTYL 4-[4-(HYDROXYMETHYL)PHENYL]TETRAHYDRO-1(2H)-PYRAZINECARBOXYLATE;4-(4-N-Boc-piperazinyl)benzyl alcohol;tert-butyl 4-(4-(hydroxymethyl)phenyl)piperazine-1-carboxylate;4-[4-(tert-Butoxycarbonyl)piperazin-1-yl]benzyl alcohol;4-[4-(Hydroxymethyl)phenyl]piperazine, N1-BOC protected, tert-Butyl 4-[4-(hydroxymethyl)phenyl]piperazine-1-carboxylate
• CAS NO: 158985-37-6
• Molecular Formula: C₁₆H₂₄N₂O₃
• Molecular Weight: 292.37
• Mol File: 158985-37-6.mol
• Article Data: 5

Chemical Properties

• Melting Point: 109 °C
• Boiling Point: 452 °C at 760 mmHg
• Flash Point: 227.2 °C
• Appearance: /
• Density: 1.152 g/cm³
• Vapor Pressure: 5.86E-09mmHg at 25°C
• Refractive Index: 1.553
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 15.05±0.10(Predicted)
• CAS DataBase Reference: TERT-BUTYL 4-[4-(HYDROXYMETHYL)PHENYL]TETRAHYDRO-1(2H)-PYRAZINECARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL 4-[4-(HYDROXYMETHYL)PHENYL]TETRAHYDRO-1(2H)-PYRAZINECARBOXYLATE(158985-37-6)
• EPA Substance Registry System: TERT-BUTYL 4-[4-(HYDROXYMETHYL)PHENYL]TETRAHYDRO-1(2H)-PYRAZINECARBOXYLATE(158985-37-6)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 158985-37-6(Hazardous Substances Data)

Usage

Description

TERT-BUTYL 4-[4-(HYDROXYMETHYL)PHENYL]TETRAHYDRO-1(2H)-PYRAZINECARBOXYLATE is a chemical compound with a complex structure, characterized by its tetrahydro-1(2H)-pyrazinecarboxylate core and a tert-butyl group. It is known for its potential applications in various industries due to its unique properties.

Uses

Used in Pharmaceutical Industry:
TERT-BUTYL 4-[4-(HYDROXYMETHYL)PHENYL]TETRAHYDRO-1(2H)-PYRAZINECARBOXYLATE is used as a reactant for the preparation of 4-[(4-piperazinobeznoyl)amino]phenyl(oxy)alkanoates. These compounds serve as fibrinogen receptor antagonists, which are important in the development of medications targeting various medical conditions, particularly those related to blood clotting and cardiovascular diseases.
The compound's role in the pharmaceutical industry is significant, as it contributes to the synthesis of potential therapeutic agents that can help in the treatment of life-threatening conditions. Its use as a reactant in the preparation of fibrinogen receptor antagonists highlights its importance in the development of novel drugs with improved efficacy and safety profiles.

InChI:InChI=1/C16H24N2O3/c1-16(2,3)21-15(20)18-10-8-17(9-11-18)14-6-4-13(12-19)5-7-14/h4-7,19H,8-12H2,1-3H3

Upstream product

• 158985-36-5 4-(4-methoxycarbonyl-phenyl)-piperazine-1-carboxylic acid tert-butyl ester 
• 162046-66-4 4-(4-(1,1-dimethylethoxycarbonyl)piperazin-1-yl)benzoic acid 
• 1257849-25-4 4-(3-formyl-phenyl)-piperazine-1-carboxylic acid tert-butyl ester 
• 197638-83-8 4-(4-(1,1-dimethylethoxycarbonyl)piperazinyl)benzaldehyde 

Downstream Products

• 1037079-04-1 tert-butyl 4-(4-((2-fluoroethoxy)methyl)phenyl)piperazine-1-carboxylate 
• 928777-12-2 diethyl (4-(4-(tert-butoxycarbonyl)piperazin-1-yl)phenyl)methylphosphonate 
• 1338466-60-6 C₂₈H₃₀N₄O₂ 

Relevant articles and documents

N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION

This invention provides Degronimers that have E3 Ubiquitin Ligase targeting moieties (Degrons) that can be linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation. The invention also provides Degrons that can be used to treat disorders mediated by cereblon or an Ikaros family protein, and methods of use and compositions thereof as well as methods for their preparation.

LIGANDS FOR IMAGING CARDIAC INNERVATION

Novel compounds that find use as imaging agents within nuclear medicine applications (PET imaging) for imaging of cardiac innervation are disclosed. These PET based radiotracers may exhibit increased stability, decreased NE release (thereby reducing side

Pyrrolo-pyridine derivatives

A class of pyrrolo[2,3-b]pyridine derivatives, substituted at the 3-position by a substituted piperazinylmethyl moiety, are antagonists of dopamine receptor subtypes within the brain, having a selective affinity for the dopamine D 4 receptor subtype over other dopamine receptor subtypes, and are accordingly of benefit in the treatment and/or prevention of psychotic disorders such as schizophrenia while manifesting fewer side-effects than those associated with classical neuroleptic drugs.